22nd Century to Present to Institutional Investors at the Citi 2018 Small & Mid Cap Conference
Henry Sicignano III, President and Chief Executive Officer of 22nd Century Group, will deliver a formal presentation to institutional investors and will discuss the Company’s recent business highlights and updates. Mr. Sicignano will also be available for one-on-one meetings with investors at the conference.
The Citi Small & Mid Cap Conference is an invitation-only event for select small-cap and mid-cap public companies. To schedule a one-on-one meeting with Mr. Sicignano, investors should contact:
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding.
22nd Century is at the center of an intense, worldwide scientific and regulatory movement in support of the Company’s long-standing mission: to reduce the harm caused by smoking. 22nd Century is the only company in the world that has grown commercial crops of proprietary VLNTM tobacco with nicotine content of just 0.4mg per gram of tobacco – at least 95% lower nicotine content than tobacco used in conventional cigarettes. Numerous independent clinical trials using 22nd Century’s proprietary SPECTRUM® research cigarettes – containing VLNTM tobacco – have shown that Very Low Nicotine content cigarettes reduce cravings, reduce consumption of cigarettes, and increase quit attempts.
In 2017, the U.S. Food and Drug Administration (FDA) announced a plan to enact a reduced nicotine mandate that will require that all cigarettes sold in the United States contain only Very Low Nicotine content tobacco with “minimally or non-addictive levels of nicotine.” At the same time, 22nd Century is preparing a revised Modified Risk Tobacco Product (MRTP) application to be submitted to the FDA in order for 22nd Century to become the first – and potentially the only – company to receive an MRTP marketing order from the FDA for a combustible cigarette.
Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2017, filed on March 7, 2018, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.
22nd Century Group
James Vail, 716-270-1523
Director of Communications